Key facts
- It has raised $12.5M; the latest was Grant ($4.8M) in Nov 2024.
- Notable investors include Bavarian Ministry of Economic Affairs and Media, Bundesministerium für Bildung und Forschung, Cancer Focus Fund, Cancer Prevention and Research Institute of Texas, EIT Health — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Eisbach
- ·The full record, as it builds
Funding rounds
No funding rounds for Eisbach are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Eisbach
Developer of novel medicines designed to target chromatin regulatory mechanisms. The company focuses on molecular vulnerabilities arising in cancer genomes by leveraging epigenetic mechanisms to stop tumor growth and support new cancer therapies, enabling healthcare professionals to address unmet clinical needs.
- Sector
- Healthcare
- HQ
- Planegg, Germany
- Founded
- 2019
- Employees
- 12
- Website
- eisbach.bio/
- Ownership
- Privately Held (backing)
Eisbach doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Eisbach shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Eisbach in its N-PORT filings yet. We sweep new filings monthly.